1. Home
  2. SPRO vs DOYU Comparison

SPRO vs DOYU Comparison

Compare SPRO & DOYU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$1.20

Market Cap

156.3M

Sector

Health Care

ML Signal

HOLD

Logo DouYu International Holdings Limited ADS

DOYU

DouYu International Holdings Limited ADS

HOLD

Current Price

$4.65

Market Cap

144.6M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPRO
DOYU
Founded
2013
2014
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Programming Data Processing
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
156.3M
144.6M
IPO Year
2017
2019

Fundamental Metrics

Financial Performance
Metric
SPRO
DOYU
Price
$1.20
$4.65
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$7.00
AVG Volume (30 Days)
2.0M
14.3K
Earning Date
05-13-2026
05-19-2026
Dividend Yield
N/A
N/A
EPS Growth
111.81
N/A
EPS
N/A
N/A
Revenue
$66,802,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$300.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
39.24
N/A
52 Week Low
$1.08
$4.28
52 Week High
$3.08
$9.00

Technical Indicators

Market Signals
Indicator
SPRO
DOYU
Relative Strength Index (RSI) 22.37 50.30
Support Level N/A $4.42
Resistance Level $2.44 $4.89
Average True Range (ATR) 0.16 0.15
MACD -0.05 0.00
Stochastic Oscillator 10.32 55.42

Price Performance

Historical Comparison
SPRO
DOYU

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About DOYU DouYu International Holdings Limited ADS

DouYu International Holdings Ltd is a game-centric live streaming platform in China and a pioneer in the eSports value chain. The company aims to build an integrated game-centric ecosystem of livestreaming, video, voice, graphic content, and other interactive and community features. The company operates the platform both on mobile apps and PC portals, through which users can enjoy immersive and interactive games and entertainment livestreaming, access a wide array of video and graphic content, and participate in community events and discussions.

Share on Social Networks: